AI-CVD vs prolaio eVO2peak Module

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-CVD

by HeartLung AI

prolaio eVO2peak Module

by Prolaio

AI Verdict

AI-CVD focuses on opportunistic screening for cardiovascular and multisystem diseases by analyzing existing CT scans for structural markers like calcium scoring and cardiac volumetry. In contrast, the prolaio eVO2peak Module estimates peak oxygen consumption using real-world data from wearable sensors to assess functional cardiovascular capacity. While both are FDA-cleared cardiology AI tools, they utilize distinct data sources and methodologies to provide different types of insights into patient cardiovascular health.

Choose AI-CVD if…

Choose AI-CVD if your primary goal is to leverage existing CT scans for opportunistic, early detection of cardiovascular and multisystem disease risks. This tool is ideal for identifying hidden health concerns like coronary artery calcium or cardiac chamber abnormalities without requiring additional imaging, radiation, or disrupting current clinical workflows.

View AI-CVD →

Choose prolaio eVO2peak Module if…

Choose prolaio eVO2peak Module if you need to longitudinally estimate a patient's peak oxygen consumption (eVO2peak) using real-world data from FDA-cleared wearable sensors. This is particularly useful for adjunctive clinical evaluation in cardiovascular care, physical medicine, or sports medicine, where understanding functional capacity and fitness over time is critical.

View prolaio eVO2peak Module →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-CVD	prolaio eVO2peak Module
Deployment	Unknown	Cloud
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AI-CVD

AI-CVD integrates seamlessly into existing CT workflows by analyzing pre-existing scans, requiring no additional patient interaction or changes to imaging protocols. In contrast, prolaio eVO2peak Module necessitates patient engagement with wearable sensors and a mobile app for data collection, introducing more steps and potential for user-dependent variability.

Clinical Value

AI-CVD

AI-CVD offers a broader spectrum of opportunistic screening for multiple cardiovascular and multisystem diseases from existing CT scans, with evidence of outperforming conventional clinical scores in predicting future events. While prolaio eVO2peak provides a valuable and validated physiological metric, its scope is more focused on a single measure.

Pricing & Value

AI-CVD

While both require contacting the vendor for pricing, AI-CVD has demonstrated established reimbursement pathways for its modules (e.g., AutoChamberu2122 and CAC detection), which significantly enhances its financial value and adoption potential for healthcare providers. Prolaio eVO2peak Module lacks this transparent reimbursement information.

Enterprise Readiness

prolaio eVO2peak Module

Both are FDA-cleared and cloud-based. However, Prolaio eVO2peak Module explicitly details adherence to several key enterprise standards beyond HIPAA and BAA, including 21 CFR Part 11, ISO 13485:2016, and MDSAP certification, demonstrating a more comprehensive approach to quality management and regulatory compliance.

Innovation

AI-CVD

AI-CVD demonstrates significant innovation by transforming existing CT scans into a comprehensive, multi-system opportunistic screening platform, extracting a wide range of cardiovascular and metabolic insights without additional patient burden. Prolaio's use of wearables for continuous eVO2peak estimation is also innovative but more focused on a specific data acquisition and metric.

Support & Docs

prolaio eVO2peak Module

Prolaio explicitly lists 'Zendesk. Documentation.' in its tech stack, suggesting a structured and dedicated system for managing support and documentation. While HeartLung has a 'Knowledge Center' and contact information, the mention of a specific, widely-used support platform by Prolaio indicates a more formalized approach.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-CVD	prolaio eVO2peak Module
Name	AI-CVD	prolaio eVO2peak Module
Company	HeartLung Corporation	Prolaio
Description	AI-CVDu00ae is an FDA-cleared, AI-powered quantitative imaging platform from HeartLung Corporation that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.	Prolaio is a clinical intelligence company that develops FDA-cleared software, such as the eVO2peak Module, to estimate peak oxygen consumption using real-world patient data for cardiovascular research and care.
Categories	Cardiology AI	Cardiology AI, Clinical Decision Support & Reference
Specialties	Cardiology, Pulmonology, Radiology	Cardiology, Physical Medicine & Rehab, Sports Medicine
Key Features	Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, No additional imaging, radiation, contrast, or workflow disruption, Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing	Estimates peak oxygen consumption (eVO2peak), Utilizes demographic data, single-lead ECG, and triaxial accelerometry inputs, Processes data from qualified third-party FDA-cleared wearable medical sensors, Applies a locked deep-learning model for eVO2peak estimation, Provides information as an adjunctive aid in clinical evaluation, Enables high-density, longitudinal data collection, Leverages real-world patient data and insights, Features FDA-cleared software and proprietary algorithms

Videos

Demos, reviews, and walkthroughs featuring AI-CVD and prolaio eVO2peak Module.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary difference in how these tools gather patient data?

AI-CVD utilizes existing chest and abdominal CT scans to perform opportunistic screening for cardiovascular and multisystem diseases. In contrast, the prolaio eVO2peak Module estimates peak oxygen consumption by processing demographic data, single-lead ECG, and triaxial accelerometry inputs from qualified third-party FDA-cleared wearable medical sensors.

What specific cardiovascular insights does each tool provide?

AI-CVD offers quantitative measurements from CT scans, including coronary artery calcium (CAC) scoring, cardiac chamber volumetry, and aortic/mitral valve calcium analysis. The prolaio eVO2peak Module provides an estimation of peak oxygen consumption (eVO2peak), which serves as an adjunctive aid in clinical evaluation for cardiovascular care.

How do these tools integrate into existing clinical workflows?

AI-CVD integrates by performing opportunistic screening using existing CT scans, aiming for no additional imaging, radiation, contrast, or workflow disruption. The prolaio eVO2peak Module processes data from remote wearable sensors, suggesting a workflow that leverages patient-generated health data collected outside the clinic.

Which patient populations or clinical scenarios are best suited for each tool?

AI-CVD is ideal for opportunistic screening of hidden cardiovascular and multisystem risks in patients who have already undergone chest or abdominal CT scans. The prolaio eVO2peak Module is designed for cardiovascular research and care, particularly for patients where longitudinal monitoring of estimated peak oxygen consumption using wearable data is beneficial.

Do these tools require additional patient procedures or equipment?

AI-CVD explicitly states it requires no additional imaging, radiation, or contrast, as it utilizes existing CT scans. The prolaio eVO2peak Module relies on data from qualified third-party FDA-cleared wearable medical sensors, which patients would need to use to provide the necessary inputs.

What specialties would primarily benefit from each tool?

AI-CVD is primarily beneficial for Cardiology, Pulmonology, and Radiology, given its reliance on CT imaging and multisystem screening capabilities. The prolaio eVO2peak Module is relevant for Cardiology, Physical Medicine & Rehab, and Sports Medicine, focusing on functional capacity assessment using wearable data.